Johnson & Johnson submitted a supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration (FDA) seeking approval for CAPLYTA (lumateperone) to treat manic or mixed episodes associated with bipolar I disorder in adults.
This filing, announced on Thursday is backed by two Phase 3 studies demonstrating rapid and sustained symptom reduction in adults with bipolar I disorder.
Bipolar disorder affects an estimated 11 million U.S. adults at some point in their lives, according to the National Institute of Mental Health (NIMH). For individuals managing Bipolar I disorder, manic episodes—characterized by grandiosity, racing thoughts, or decreased need for sleep—can escalate quickly, often requiring hospitalization for patient safety and stability.
CAPLYTA Shows Rapid Improvement in Bipolar Mania Symptoms
- CAPLYTA is a medication being reviewed for its use in treating manic episodes associated with Bipolar I disorder.
- Clinical data indicates that symptoms can show significant improvement as early as Day 3 of treatment.
- This filing seeks to expand CAPLYTA’s approved uses to include manic episodes, potentially making it a foundational therapy across the illness’s course.
The sNDA, which is supported by two key Phase 3 studies (Study 451 and Study 452), uses data gathered during randomized, double-blind, placebo-controlled research. These studies investigated the efficacy of once-daily CAPLYTA 42 mg against a placebo in adults experiencing manic or mixed episodes associated with Bipolar I disorder.
The research concluded that CAPLYTA met both the primary and key secondary endpoints in both trials, showing significant improvement in both overall illness severity and specific manic symptoms versus placebo.
The Clinical Efficacy of Lumateperone in Acute Mania
The Phase 3 studies, which were posted presented at major psychiatric congresses in 2026, provided strong evidence supporting this action in the context of acute mania.

One of the most compelling findings detailed in the filing is the speed of response. Improvement in manic symptoms was observed as early as day 3 following only two days of treatment. Furthermore, this clinical improvement was sustained through Week 3 of the study period.
“For people experiencing acute mania, rapid symptom improvement and tolerability are both critical treatment considerations,” said John C. Reed, M.D., Ph.D., Executive Vice President of Innovative Medicine, R&D, at Johnson & Johnson.
John C. Reed, M.D., Ph.D., Executive Vice President of Innovative Medicine, R&D, at Johnson & Johnson, stated regarding the findings: “Our Phase 3 results demonstrate the potential for CAPLYTA to address these needs, and this submission advances our ambition to provide a foundational treatment that can support patients across the evolving course of serious psychiatric disorders.”
| Trial Metric | CAPLYTA (42 mg) | Placebo | Key Finding |
|---|---|---|---|
| Symptom Reduction | Significant | None | Met primary/secondary endpoints in both studies. |
| Onset of Improvement | As early as Day 3 | N/A | Rapid onset demonstrated. |
| Sustained Efficacy | Sustained through Week 3 | N/A | Long-term effectiveness observed in trials. |
Expanding CAPLYTA’s Regulatory Footprint Across Indications
The submission of this sNDA would mark the fifth approved use for CAPLYTA in adults. Currently, CAPLYTA is approved for managing depressive episodes associated with Bipolar I or II disorder, as well as major depressive disorder (MDD) and schizophrenia. The filing seeks to expand its scope to encompass manic or mixed episodes associated with Bipolar I disorder.
The current safety and tolerability profile of CAPLYTA has been established across various indications, which helps support the argument for its use in mania. The company reported low rates of discontinuation due to adverse events and maintained a safety profile consistent with prior, established studies.
This extensive safety data is crucial for regulatory bodies like the FDA (U.S. Food and Drug Administration) when evaluating new indications for serious psychiatric conditions.
The trials, Study 451 and Study 452, were designed as randomized, double-blind, placebo-controlled studies, which is the gold standard in clinical research. These studies measured primary endpoints, such as the Young Mania Rating Scale (YMRS) total score at Week 3, and key secondary endpoints, such as the change from baseline in the Clinical Global Impression-Severity (CGI-S) score at Week 3. Meeting these statistically defined benchmarks is necessary for regulatory approval.
FDA Review Will Decide CAPLYTA Approval for Bipolar Mania
The FDA’s review of this sNDA will determine if CAPLYTA can become an approved, standard treatment for bipolar mania. While the data presented by Johnson & Johnson in the filings show strong efficacy, the regulatory process requires comprehensive review of all clinical data, manufacturing processes, and risk-benefit profiles.
The United States has a significant need for effective treatments, given the prevalence of bipolar disorder. Regulatory bodies, such as the U.S. Food and Drug Administration, will review the data from Study 451 and Study 452 to determine if the medication should be approved for manic or mixed episodes associated with bipolar I disorder in adults.
Contraindications & When to Consult a Doctor
The official safety information noted in the filing includes several critical risks.
Specifically, the labeling identifies increased mortality risks for elderly patients living with dementia-related psychosis. There is also a specific warning regarding an increased risk of suicidal thoughts and actions in people aged 24 years and younger. These risks necessitate careful risk-benefit assessment prior to prescribing the medication.
Johnson & Johnson, headquartered in New Brunswick, New Jersey, traces its origins to 1886, when Robert Wood Johnson joined his brothers James Wood Johnson and Edward Mead Johnson to found the company with 14 employees—eight women and six men. The firm manufactured the world’s first sterile surgical products and designed the first commercial first aid kit in 1888 for railroad construction workers often hundreds of miles from medical care.
Today, the American multinational pharmaceutical, biotechnology, and medical technologies corporation is one of only two U.S.-based companies, alongside Microsoft, holding a prime credit rating of AAA from S&P Global, and it is behind the sNDA filing for CAPLYTA now before the FDA.
While the Phase 3 data is highly encouraging regarding rapid efficacy, the final decision to approve CAPLYTA for this indication rests entirely with the FDA’s rigorous review process.
References
- Johnson & Johnson seeks U.S. FDA approval for CAPLYTA in bipolar mania, marking fifth potential indication. News release. November 19, 2026.
- Cutler AJ, Earley WR, Hayes R, et al. In a randomized, double-blind, placebo-controlled, phase 3 study, lumateperone was evaluated for manic episodes, whether or not mixed features were present, in bipolar I disorder. Psych Congress 2026.
- McIntyre RS, Earley WR, Hayes R, et al. A randomized, double-blind, placebo-controlled phase 3 study assessed lumateperone as a therapy for bipolar mania among individuals diagnosed with bipolar I disorder. NEI Fall Congress 2026.
- Bipolar disorder. National Institute of Mental Health.